Moors & Cabot
AXSM icon

Moors & Cabot’s Axsome Therapeutics AXSM Stock Holding History

Moors & Cabot’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$411K Sell
2,230
-100
-4% -$21.8K 0.02% 634
2026
Q2 		$570K Hold
2,330
– – 0.02% 529
2026
Q1 		$394K Sell
2,330
-100
-4% -$17.3K 0.02% 612
2025
Q4 		$444K Buy
2,430
+50
+2% +$6.98K 0.02% 574
2025
Q3 		$289K Buy
2,380
+50
+2% +$5.63K 0.01% 685
2025
Q2 		$243K Buy
2,330
+100
+4% +$10.6K 0.01% 725
2025
Q1 		$260K Buy
+2,230
New +$254K 0.01% 689
2024
Q4 		– Sell
-2,230
Closed -$200K – 890
2024
Q3 		$200K Buy
+2,230
New +$195K 0.01% 804

Other funds holding AXSM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Moors & Cabot's AXSM Position: Q3 2026 in Review

Moors & Cabot reduced its Axsome Therapeutics (AXSM) stake by 4.3% in Q3 2026, selling an estimated $21.8K and leaving 2,230 shares worth $411K. The position accounts for 0.02% of the portfolio, ranked #634.

Moors & Cabot first reported a position in AXSM in Q3 2024 and has held it in 8 quarters since. The position peaked at $570K in Q2 2026. 185 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Moors & Cabot held 2,230 shares of Axsome Therapeutics worth $411K as of Q3 2026.
  • Moors & Cabot sold 100 Axsome Therapeutics shares in Q3 2026, an estimated $21.8K.
  • Axsome Therapeutics made up 0.02% of Moors & Cabot's portfolio in Q3 2026, its #634 holding.
  • Moors & Cabot first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Moors & Cabot's Axsome Therapeutics position peaked at $570K in Q2 2026.
  • 185 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.